Neurocrine’s newly approved Parkinson’s drug suffers launch delay due to Covid-19

28 April 2020 (Last Updated April 28th, 2020 14:21)

Neurocrine Biosciences has announced it has received FDA approval for Ongentys (opicapone), an oral drug used as an add-on treatment to the standard-of-care drug, levodopa, in patients with Parkinson’s disease experiencing end-of-dose motor fluctuations. However, the company will not launch the drug until later this year, due to Covid-19 disruption.

GlobalData predicts that if the drug launches later in 2020 it will have a slow uptake in its first year, reaching peak global sales of $303M in 2025.